PMID- 30941192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2019
DP  - 2019
TI  - Antihyperlipidemic and Antioxidative Potentials of Onion (Allium cepa L.) Extract 
      Fermented with a Novel Lactobacillus casei HD-010.
PG  - 3269047
LID - 10.1155/2019/3269047 [doi]
LID - 3269047
AB  - The purpose of this study was to investigate antihyperlipidemic and antioxidative 
      potentials of onion (Allium cepa L.) extract fermented with a novel Lactobacillus 
      casei HD-010. In general, fermented onion extract is used for its antioxidative 
      activity (ORAC), inhibitory effect on adipocytes differentiation, quercetin 
      contents, and antihyperlipidemic activities. However, the effect of fermented 
      onion extract on hyperlipidemia after oral administration using ApoE-deficient 
      mice has not been reported yet. To understand the effect of fermented onion 
      extract on hyperlipidemia, we used benzafibrate (10 mg/kg, bw/day) as a positive 
      control in the present study. Serum was collected every week to analyze levels of 
      low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), 
      and cholesterol, 3-hydroxy-3-methylgutaryi-CoA (HMG-CoA) reductase activity, and 
      cholesterol ester transport protein (CETP) activity. In the fermented 
      onion-treated group, HDL level was significantly increased while levels of TG and 
      LDL were significantly decreased compared to those in the control group. In 
      addition, the inhibition activity of HMG-CoA reductase was increased 20% in the 
      fermented onion-treated group at 100 mg/kg. CETP activity has been observed to be 
      significantly inhibited in the fermented onion-treated groups compared to that in 
      the control group. These results suggest that fermented onion has a 
      preventive/therapeutic effect on hyperlipidemic disease. It might have potential 
      to be developed as a functional food.
FAU - Yang, Woong-Suk
AU  - Yang WS
AD  - Nodaji Co., Ltd., Pohang, Gyeongbuk, Republic of Korea.
AD  - School of Life Sciences and Biotechnology, Kyungpook National University, Daegu, 
      Republic of Korea.
FAU - Kim, Jin-Chul
AU  - Kim JC
AD  - Natural Constituents Research Center, Natural Products Research Institute, Korea 
      Institute of Science and Technology, Gangneung, Republic of Korea.
FAU - Lee, Jae Yong
AU  - Lee JY
AD  - Department of Advanced Aerospace Materials Egineering, Kyungwoon University, 
      Gumi, Gyeongbuk, Republic of Korea.
FAU - Kim, Cheorl-Ho
AU  - Kim CH
AUID- ORCID: 0000-0002-6323-0714
AD  - Department of Biological Sciences, College of Science, SungKyunKwan University, 
      Seoburo 2066, Jangan-Gu, Suwon 16419, Republic of Korea.
FAU - Hwang, Cher-Won
AU  - Hwang CW
AUID- ORCID: 0000-0001-6917-7849
AD  - Department of AGEE, Handong University, Pohang, Gyeongbuk, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20190303
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC6421041
EDAT- 2019/04/04 06:00
MHDA- 2019/04/04 06:01
PMCR- 2019/03/03
CRDT- 2019/04/04 06:00
PHST- 2018/08/30 00:00 [received]
PHST- 2019/01/04 00:00 [revised]
PHST- 2019/02/10 00:00 [accepted]
PHST- 2019/04/04 06:00 [entrez]
PHST- 2019/04/04 06:00 [pubmed]
PHST- 2019/04/04 06:01 [medline]
PHST- 2019/03/03 00:00 [pmc-release]
AID - 10.1155/2019/3269047 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2019 Mar 3;2019:3269047. doi: 
      10.1155/2019/3269047. eCollection 2019.